Phage Cocktail Development for Bacteriophage Therapy: Toward Improving Spectrum of Activity Breadth and Depth
- PMID: 34681243
- PMCID: PMC8541335
- DOI: 10.3390/ph14101019
Phage Cocktail Development for Bacteriophage Therapy: Toward Improving Spectrum of Activity Breadth and Depth
Abstract
Phage therapy is the use of bacterial viruses as antibacterial agents. A primary consideration for commercial development of phages for phage therapy is the number of different bacterial strains that are successfully targeted, as this defines the breadth of a phage cocktail's spectrum of activity. Alternatively, phage cocktails may be used to reduce the potential for bacteria to evolve phage resistance. This, as we consider here, is in part a function of a cocktail's 'depth' of activity. Improved cocktail depth is achieved through inclusion of at least two phages able to infect a single bacterial strain, especially two phages against which bacterial mutation to cross resistance is relatively rare. Here, we consider the breadth of activity of phage cocktails while taking both depth of activity and bacterial mutation to cross resistance into account. This is done by building on familiar algorithms normally used for determination solely of phage cocktail breadth of activity. We show in particular how phage cocktails for phage therapy may be rationally designed toward enhancing the number of bacteria impacted while also reducing the potential for a subset of those bacteria to evolve phage resistance, all as based on previously determined phage properties.
Keywords: JavaScript; antimicrobial resistance; bacteriophage therapy; combating resistance; combination therapy; host range; online apps; quantitative biology.
Conflict of interest statement
S.T.A. has consulted for and served on advisory boards for companies with phage therapy interests, holds an equity stake in a number of these companies, and maintains the websites phage.org and phage-therapy.org. No additional competing financial interests exist. The text presented represents the perspectives of the authors alone, and no outside help was received in its writing.
Figures






References
-
- Kincaid R. Treatment and prevention of bacterial infections using bacteriophages: Perspectives on the renewed interest in the United States. In: Górski A., Miedzybrodzki R., Borysowski J., editors. Phage Therapy: A Practical Approach. Springer; Cham, Switzerland: 2019. pp. 169–187.
-
- Górski A., Miedzybrodzki R., Borysowski J. Phage Therapy: A Practical Approach. Springer Nature; Cham, Switzerland: 2019.
-
- Rogóz P., Amanatullah D.F., Miedzybrodzki R., Manasherob R., Weber-Dabrowska B., Fortuna W., Letkiewicz S., Górski A. Phage therapy in orthopaedic implant-associated infections. In: Górski A., Miedzybrodzki R., Borysowski J., editors. Phage Therapy: A Practical Approach. Springer; Cham, Switzerland: 2019. pp. 189–211.
-
- Duplessis C.A., Biswas B. A review of topical phage therapy for chronically infected wounds and preparations for a randomized adaptive clinical trial evaluating topical phage therapy in chronically infected diabetic foot ulcers. Antibiotics. 2020;9:377. doi: 10.3390/antibiotics9070377. - DOI - PMC - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources